Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Learn about the Prescription Drug Affordability Board’s (PDAB) mission, members, and upcoming meetings.
Stay up to date on what's happening with PDAB.
PDAB’s mission is to monitor and mitigate unsupported price increases of prescription drugs for Washingtonians.
PDAB is composed of three bodies:
PDAB was established following passage of SB5532 by the Washington State Legislature in 2022.
PDAB is a five-member board tasked with the following duties:
To date, the PDAB has used the requirements laid out in the authorizing legislation, Washington Administrative Code, and PDAB policies to create a list of eligible drugs for review. The PDAB is currently in the process of narrowing down this long list of eligible prescription drugs to a shortlist of drugs that will be selected for affordability review. The next steps in the process will be conducting affordability reviews on selected drugs. The drug dashboard provides resources to explore the list of eligible drugs. Once drugs are selected for review, the drug names will be listed on this website.
Date, time, and location | Meeting materials |
---|---|
Date: July 15, 2025 |
Written public comments |
May 21, 2025 |
Written public comments |
January 15, 2025 |
Written public comments |
Date, time, and location | Meeting materials |
---|---|
December 11, 2023 |
|
October 20, 2023 |
Date, time, and location | Meeting materials |
---|---|
Date: August 12, 2025 Time: 2 - 4 p.m. Online: Join the meeting |
|
December 10, 2024 | |
October 8, 2024 |
The Board of Directors is nominated for service by the Governor. Four of five members have been appointed.
Hung Truong is the executive director of Madrona Health, LLC., a joint venture between Virginia Mason Franciscan Health and Confluence Health. He earned his Pharm.D. from Washington State University and MBA from Western Governors University.
In 2017, Hung launched the specialty pharmacy program that led to the formation of Madrona Health.
Dr. Douglas Barthold is a health economist and research assistant professor in the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington School of Pharmacy.
Dr. Barthold's research includes health policy, chronic disease management, and cognition from mid-life to end of life. He also researches the role of health policies in pharmaceutical management of mid-life risk factors for Alzheimer's disease and related dementias (ADRD) and the value of care for conditions that influence health aging.
Eileen Cody worked as a neuro-rehab nurse for Kaiser Permanente (formerly Group Health Cooperative) in Seattle for more than 40 years. She served constituents in the 11th and 34th districts as an elected representative from 1994-2022. Eileen earned an Associate Degree in Nursing from the College of Saint Mary and a Bachelor of Science in Nursing from Creighton University.
Greg Gipson has worked at UW Medicine since 2013, initially as a clinical pharmacist caring for critically ill patients with a wide variety of health conditions, and now focusing on drug policy and utilization. His current work aims to improve the use of medications to promote safer, more effective, and cost-conscious practices that result in improved health outcomes across the health system.
A stakeholder webinar meeting was held to discuss the prescription drugs affordability review process.
The PDAB board selected the following drugs for affordability review and will be moving sequentially through the drugs:
If you would like to give testimony but cannot attend a meeting, email a one-page maximum testimony to HCA PDAB.
If you would like to speak on any topic listed on the agenda, email HCA PDAB by the Monday before the meeting date with:
The committee chair will call these names after the topic is presented. You will be unmuted and have three minutes to speak.
If you do not sign up ahead of time but would like to speak at the meeting, the committee chair will ask if there are any other stakeholders. Raise your hand and you will be unmuted when your name is called.
For questions about the board
Email: HCA PDAB